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We previously reported (1, 2) that normally noncytotoxic mononuclear cells from 
human peripheral blood and a heat-labile, nonantibody factor(s) present in normal 
human serum can cooperate in vitro to lyse a variety of xenogeneic erythrocyte target 
cells.  Because neither serum nor the mononuclear cells alone cause significant target 
lysis, we termed this cytotoxic system synergistic cytotoxicity. In our earlier studies, 
we showed that the serum factor active in this system was labile to heating (56°C, 30 
min)  and  to  treatment  with  zymosan  mad  cobra  venom  factor,  required  divalent 
cations, and was present in agammaglobulinemic sera and sera depleted of immuno- 
globulins  by  affinity  chromatography.  Both  monocytes  and  T  lymphocytes were 
found  to  kill  xenogeneic  erythrocytes  in  the  presence  of these  active  sera.  One 
particularly  intriguing  finding  of these  earlier  studies  was  the  observation  that 
antibodies to factor B of the alternative complement pathway, when  added to the 
active normal  serum,  substantially  inhibited  target  cell lysis in  this  system.  These 
observations suggested a previously unrecognized link between elements of two major 
nonimmune host  defense systems, the alternative complement pathway and poten- 
tially cytotoxic mononuclear cells. 
This report presents studies further characterizing the serum factors active in this 
system by using sera deficient in, or depleted of, single complement components and/ 
or highly purified individual complement components tested with purified lympho- 
eytes, monocytes, or mixtures of the two cell types, 
Materials and Methods 
Media.  RPMI 1640 and Hanks' balanced salt solution were purchased from Microbiological 
Associates, Bethesda MD. Hepes buffer was from Gibco Laboratories, Grand Island Biological 
Co., Grand Island, NY. 
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Serum Samples.  As previously described (1), both heparinized human plasma (20 U/ml) and 
serum  from  normal  individuals support  synergistic cytotoxicity equally well.  Human  sera 
deficient in C3, C5, C7, and C8 were obtained from genetically deficient individuals and have 
been previously described (3-7). C4-deficient guinea pig serum was obtained from genetically 
deficient guinea pigs (8).  Normal  human  serum was depleted of factor B  using solid-phase 
F(ab')2 anti-factor B  immunoabsorbent columns as described (15).  Factor D-depleted serum 
was prepared by gel filtration (9). All sera or plasmas were absorbed four times against  1/3 
volume of packed target erythrocytes on ice, as previously described, to remove any target cell- 
specific antibody (1). All serum and plasma sources were tested for residual antibody contam- 
ination by the ability of heat treatment (56°C, 30 min) to abolish lysis of target cells by human 
mononuclear cells in the absorbed plasma. Such treatment does not affect antibody-dependent 
cellular cytotoxicity (ADCC)  (1).  By these criteria, all of the serum and plasma sources were 
totally depleted of target-specific antibody. 
Sources of Antibodies.  Goat anti-C3 and anti-C5 antisera were purchased from Miles Labo- 
ratories Inc., Elkhardt, IN. Goat anti-factor B antiserum was purchased from Atlantic Anti- 
bodies, Scarborough, ME. A high titer mouse monoclonal hybridoma antibody directed against 
C3 purified from tissue culture supernatants was kindly provided by Dr. J. D. Capra, University 
of Texas Health Science Center, Dallas, TX.  1 mg of this antibody inactivates > 1 mg of C3 
detected by hemolytic assay (14).  All antibodies were absorbed against chicken erythrocytes 
and were heat-inactivated (56°C, 30 min) before use. 
Cytotoxicity Assay.  Cytotoxicity was performed using blCr-labeled chicken erythrocyte targets 
in an  18-h SlCr-release assay run at a  target-to-effector cell ratio of 1:I0, as described (1,  2). 
When serum or plasma were tested for ability to support synergistic cytotoxicity, 25/xl of a  1:5 
dilution  in  medium  was  added  to  each  microtiter well  (total  volume,  200  ~l/well).  Some 
experiments contained added antiserum (25/xl of 1:5 dilution) or monoclonal anti-C3 (25/xl of 
solution  containing  140  /tg  antibody/ml).  In  these experiments,  wells with  human  serum, 
antiserum or monoclonal antibody, and effector leukocytes were allowed to incubate 30 min at 
37°C before adding targets. 
Assays were performed in  triplicate in serum-free RPMI  1640  with added penicillin (50 
U/ml), streptomycin (50/~g/ml), and glutamine  (4 mM)  and were harvested on  a  Titertek 
supernatant  collection system  (Flow Laboratories, Bethesda, MD).  Results are expressed as 
mean  percent 51Cr release compared with  total detergent-releasible counts.  All assays were 
performed in triplicate, with --<5% variability. 
Purified Factor B and C5.  Purified human factor B was prepared from normal human serum 
as  previously described  by  Kerr  and  Porter  (16).  Factor B  was  diluted  in  medium  to  a 
concentration approximately that of normal serum (titer 40,000)  and used in 6-25 #1 aliquots 
per microtiter well.  Most  factor B  preparations exhibited single bands  on  sodium  dodecyl 
sulfate-polyacrylamide gel electropheresis, some  preparations had  an  additional faint  band 
consistent with the major cleavage product of factor B  (Bb). C5 was prepared from normal 
human serum, according to published techniques (17), and further passed over immunoabsor- 
bent columns of anti-C3, anti-C6, and Staphylococcal protein A. C5 preparations were free of 
other detectable complement components by hemolytic assay (14). 
Preparation of Cells.  Whole mononuclear cells were prepared by buoyant density centrifu- 
gation using lymphocyte separation medium (Litton Bionetics, Kensington, MD)  (1).  Mono- 
cyte-enriched populations were obtained from whole mononuclear cell preparations by adher- 
ence to plastic petri dishes in RPMI  1640 containing 10% heat-inactivated fetal bovine serum 
with added Hepes buffer (10 mM), penicillin, streptomycin, and glutamine. Monocytes were 
allowed to adhere for 60 min at 37°C. The nonadherent ceils (lymphocytes) were gently washed 
off with warm phosphate-buffered saline, and the residual cells were then  incubated with a 
buffered EDTA solution (Versene;  Gibco Laboratories, Grand Island Biological Co.)  for 20 
min, followed by vigorous aspiration with a pasteur pipet. All cells were washed two additional 
times in Hanks' balanced salt solution. Monocyte-enriched preparations contained from  75- 
95% alpha naphthyl butyrate esterase-positive cells (10). The nonadherent lymphocyte popu- 
lation contained <5% esterase-positive cells. 
The RPMI 1056 human B cell line was kindly supplied by Dr. Stanley Korsmeyer, National 
Institutes of Health.  The line was grown  in RPMI  1640  medium containing  10%  fetal calf 836  COMPLEMENT-MONONUCLEAR CELL COOPERATIVE CYTOTOXICITY 
serum, penicillin,  streptomycin, and glutamine. Cells were collected  at 300 g for 10 min and 
washed three times with Hanks' balanced salt solution before use. 
Results 
C5-deficient  and Factor  B-depleted  Sera  Do Not  Support  Synergistic  Cytotoxicity  by  Whole 
Mononuclear  Cells.  To further characterize the serum requirements for the expression 
of synergistic cytotoxicity, we performed a  series of experiments that  examined the 
ability of human sera deficient in single complement components to support cytotox- 
icity in the presence of human mononuelear leukocytes. Table I presents a summary 
of these  experiments.  As can  be seen,  of the  genetically deficient  sera tested,  only 
serum deficient in C5 failed to support some target cell lysis by mononuclear effector 
cells. By marked contrast, normal serum and serum deficient in C3 cooperated with 
mononuclear cells in causing target cell lysis.  Sera deficient  in  C4,  C7,  and C8  all 
supported  some target  cell  lysis, but  usually  less  than  normal  serum.  It should  be 
noted, however, that the range of activity found in sera from various normal subjects 
is broad in this assay. In 30 assays on  11  different  normal sera, mean percent  51Cr 
release was 55.2,  with a  standard  deviation of 23.9.  Also of note is that some of the 
deficient sera had been stored at  -90°C  for periods  in  excess of 1 yr, which  could 
potentially affect the activity. 
Table ! also includes the results of studies of sera depleted of factor B  (by affinity 
chromatography)  and of factor D  (by gel filtration).  Factor D-depleted serum sup- 
ported moderate levels of target lysis, whereas serum depleted of factor B was totally 
inactive in this lytic system. As shown in our earlier studies (1, 2), antibody to factor 
B was markedly inhibitory to target cell lysis. Table II demonstrates that antibodies 
to C5  also inhibit  target cell lysis in  this cytotoxic system. Thus, these experiments 
indicate that both C5 and factor B appear to be essential serum components for target 
cell lysis by unfractionated mononuclear effector cell populations. 
TABLE  I 
Synergistic Cytotoxicity by Whole Mononuclear Cell Effectors m the Presence of 
Complement-deficient Sera 
Serum  Percent SlCr-specific  Number of 
release  experiments 
C3-deficient  66.7 ±  7.4  3 
C4-deficient (guinea pig)  47.0 ±  7.5  3 
C5-deficient  0.5 ±  0.5  4 
C7-deficient  25.3 ±  1.8  3 
C8-deficient  37.3 ±  4.1  3 
Factor B-depleted  2.0 ±  2.0  5 
Factor D-depleted  30.3 ±  17.3  3 
Normal  55.2 ±  4.4*  30 
Results expressed as mean percent ~lCr release (+  1 SE)  of several experi- 
ments  run  in  triplicate.  Concurrently,  normal  sera  were  tested  in  each 
experiment.  Spontaneous lysis of SlCr-labeled  chicken  erythrocytes in  the 
presence of serum-free mononuclear cells  has been  subtracted  from  each 
value (spontaneous lysis ranged from 4-14%; mean, 7.2).  Control sera were 
from 11 normal individuals, whereas deficient sera were from single individ- 
uals. Two different preparations of factor B-depleted sera were tested, with 
similar results in each case. 
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TABLE II 
Synergistic Cytotoxicity:  Effect of Adding Anti-C3  To Normal and C3-deficient Sera 
837 
Addition 
Percent 5XCr release 
Experiment  Experiment  Experiment  Experiment  Experiment 
1  2  3  4  5 
Medium  7  5  12  8  11 
N1 plasma*  38  37  65  78  39 
NI plasma + anti-C3 (I)  49  --  --  72  -- 
N1 plasma + anti-C3 (II)  71  .... 
N1 plasma + anti-factor B  12  .... 
N1 plasma + anti-C5  7  .... 
C3-deficient serum  --  77  78  --  63 
C3-deficient serum +  anti-C3  --  68  59  --  -- 
(I) 
C3-defieient serum +  anti-C3  ....  91 
(II) 
Anti-C3 (I) alone  6  --  12  6  -- 
Anti-C3 (II) alone  7  --  --  --  7 
Five separate experiments showing that anti-C3 fails to abrogate synergistic cytotoxicity. Experiments 1- 
4 used whole mononuclear cell effectors; purified monocytes were tested in experiment 5. Anti-C3 (I) is 
a monoclonal mouse antibody, and anti-C3 (II) is a goat antiserum. Note that neither of the anti-C3 
antibodies by themselves induced any cytotoxicity. 
* N1 plasma (normal plasma)  used in all experiments except experiment 1, in which normal serum was 
used. Normal plasma and serum support synergistic cytotoxieity equally well. 
Anti-C3 Antibodies  Do Not Inhibit Synergistic  Cytotoxicity  in the Presence of Normal or C3- 
deficient  Serum.  The  apparent  lack  of  a  requirement  for  C3  suggested  a  unique 
pathway  for activity of the serum complement system.  Because genetically deficient 
plasma  may still contain small amounts  of C3  and  because normal  monoeytes can 
synthesize C3  (11),  we  asked  whether  such  small  amounts  could  suffice  to  support 
synergistic cytotoxicity. To address this question, antibodies to C3 were added to the 
C3-deficient serum. Two sources of anti-C3 antibody, one a  goat heteroantiserum and 
one a  mouse monoclonal anti-C3, were used. These antibodies were added to cells in 
the  presence  of target-absorbed  normal  human  serum  or human  serum  genetically 
deficient in C3.  With both sources of antibody, killing was not inhibited (Table II). 
In contrast, anti-C5 and anti-factor B  markedly inhibited synergistic target  cell lysis. 
1 mg of the mouse monoclonal anti-C3 was capable of inhibiting >1  mg of hemolyt- 
ically  active  C3  (fluid-phase  sheep  cell  assay;  data  not  shown).  Because  the  C3- 
deficient serum had undeteetable immunochemical or hemolytically active C3 (<0.1% 
of activity in  normal  serum),  the  amount  of monoclonal anti-C3  used  in Table  II 
would be sufficient to inactivate >1,000 times the amount  of C3 potentially present 
in  C3-deficient  serum  used,  assuming  the  C3-deficient  serum  contained  C3  at  a 
concentration just below the limit of detection. 
We next performed a series of experiments to determine whether the sera that failed 
to support synergistic cytotoxicity could be reconstituted. Initially, C5-deficient serum 
was mixed with an equal volume of factor B-depleted serum. This mixture was fully 
active  in  the  cytolytic  assay  (Fig.  1),  indicating  that  the  lack  of activity  in  each 
separate serum was probably not due to the presence of some inhibitory substance. A 
more direct  approach  was  to reconstitute each  deficient serum with the appropriate 
purified  component.  As  also  shown  in  Fig.  1,  each  deficient  serum  regained  full 838  COMPLEMENT-MONONUCLEAR CELL COOPERATIVE  CYTOTOXICITY 
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Fro.  1.  Whole  mononuclear cell effector populations exhibited cytotoxicity  when factor B-depleted 
or C5-deficlent  sera were reconstituted with the appropriate factors. Results are expressed as percent 
S~Cr release. Factor B and C5 were added to reconstitute the deficient serum to physiological  levels 
of each component. Representative experiment of four similar studies. 
F[o.  2.  (a) Cytotoxicity  assays were performed in the presence or absence of 25/~1 of purified factor 
B (titer 40,000) in serum-free medium. Final volume is 0.2 ml/microtiter well. Target-to-effector 
ratio was 1  : 10 using 3 X 105 enriched monocytes  as effectors. (b) Dose-response  of factor B-induced 
monocyte cytotoxicity.  Varying amounts of factor B solution (titer 40,000) in medium were added 
to a microcytotoxicity  assay using 3 ×  105 enriched monocytes. SlCr release in the presence of 
medium alone (12%) was subtracted from each point to yield percent specific  S~Cr release. 
i 
3O 
activity after reconstitution with its missing component. 
C5-deficient Serum Supports Synergistic Cytotoxicity by Monocytes but Not by Lymphocytes. 
Because our previous data had shown that both monocytes and lymphocytes could 
mediate  target  cell  lysis,  we  examined  the  effects  of deficient  sera  on  monocyte- 
enriched and lymphocyte-enriched populations. As can be seen in Table III, factor B- 
depleted serum failed to support significant killing by either monocytes or lympho- 
cytes. Surprisingly, C5-deficient serum supported monocyte-mediated lysis of target 
cells but failed to support lymphocyte-dependent target cytolysis (compare with Fig. 
1).  C7-  and  C8-deficient  sera  supported  monocyte-mediated cytolysis,  albeit  less 
effectively than whole serum, while failing to support lymphocyte-mediated cytolysis. 
As noted previously, many of these deficient sera had been stored in the freezer for 
prolonged periods,  which  potentially could contribute to  the  depressed  activity in 
these studies. Mixing factor B-depleted serum with either C7-deficient or CS-deficient 
serum reconstituted full activity of lymphocyte-mediated  cytolysis, thus, again making 
unlikely the possibility of an inhibitor in these deficient sera. Sufficiently purified C7 
and C8 were not available to test whether lymphocyte-mediated cytotoxicity may be 
reconstituted by adding purified components to these deficient sera. Thus, these data HALL,  BLAESE,  DAVIS,  DECKER,  TACK,  COLTEN,  AND  MUCHMORE 
TABLE  III 
Failure of Factor B-depleted Sera to Support Lysis of Xenogeneic Targets by Separated 
Monocytes or Lymphocytes 
839 
Experiment  Serum or plasma source 
Percent specific SlCr 
release 
Monocytes  Lymphocytes 
1  Normal  52  54 
Factor B-depleted  8  3 
C7-deficient  23  0 
C8-deficient  38  0 
C7-deficient +  B-depleted  --  46 
CS-deficient +  B-depleted  --  48 
Factor D-depleted  25  39 
2  Normal  91  85 
C3-deficient  60  31 
C5-deficient  22  8 
Synergistic cytotoxicity by separated monocytes and lymphocytes showing the results 
of two representative experiments. The background lysis in the absence of plasma but 
presence  of cells  has  been  subtracted  to  yield  percent  specific  5~Cr release.  For 
experiment 1, the background release was 8% and 10% 5aCr release for monocytes and 
lymphocytes, respectively; for experiment 2, the lysis was 9% and 4%, respectively. 
TABLE  IV 
Inhibition of Factor B-induced Monocyte Cytotoxicity by Peripheral Blood Lymphocytes 
Addition 
Percent 51Cr release 
Experiment  Experiment  Experiment 
1  2  3 
Monocytes +  medium  8  12  12 
Monocytes +  factor B  32  61  59 
Mononuclear cells +  medium  1 1  --  -- 
Mononuclear cells +  factor B  6  --  -- 
Monocytes +  mononuclear ceils +  factor B  7 (100)  --  -- 
Lymphocytes +  medium  --  10  -- 
Lymphocytes +  factor b  --  10  -- 
Monocytes +  lymphocytes +  medium  --  11  12 
Monocytes +  lymphocytes +  factor B  --  22 (77)  24 (73) 
Three separate experiments demonstrating inhibition of factor B-induced monocyte-medi- 
ated cytotoxicity by lymphocytes. Peripheral blood monoeytes (3 ×  10  r) were added to the 
designated wells in the presence or absence of 25 #1 of factor B (titer 40,000/ml). Mononuclear 
cells or lymphocytes (1.5 ×  10  ~) were added to some of the wells. Percent inhibition of factor 
B-induced  monocyte-mediated  cytotoxicity  by  lymphocytes  (given  in  parentheses)  was  5~  calculated after subtraction of background  Cr release.  Control experiments with a human 
B cell line (RPMI 1056) were also performed in separate experiments to control for potential 
crowding and gave 4%, 2%, and 0% suppression. 
indicate  that,  in  this  type  of  cytotoxicity,  monocytes  require  factor  B,  whereas 
lymphocytes  require factor B  and,  in addition,  at least C5, C7, and  C8. 
Purified Factor B Induces Cytotoxicity  by Monocytes  but Not by Lymphocytes.  These results 
suggested  that  purified  factor  B  by  itself might  support  cytotoxicity  by  monocyte- 
enriched cell populations. As seen in Fig. 2 a, purified monocytes were, in fact, induced 
to become cytotoxic in the presence of purified factor B  alone (the assay system being 840  COMPLEMENT-MONONUCLEAR CELL  COOPERATIVE  CYTOTOXICITY 
otherwise free of other added serum factors). In contrast, purified factor B alone failed 
to support cytolysis mediated by lymphocytes (Fig, 2 a and Table IV). Fig. 2 b shows 
a dose-response curve for the induction of monocyte-mediated cytotoxicity by factor 
B.  As  little as  3 ~1  of the factor B  solution  (titer 40,000)  was  capable of inducing 
measurable  monocyte-mediated  target  cell  lysis  under  these  conditions  (3  ×  105 
monocytes; target/effector ratio of 1:10). 
Lymphocytes Inhibit Factor B-induced Monocyte-mediated Cytotoxicity.  The demonstration 
that factor B alone induced monocytes to become cytotoxic was unexpected because 
we had  repeatedly observed that  factor B  failed to induce whole mononuclear cell 
preparations to become cytotoxic and because whole mononuclear cells contain  15- 
40% monocytes. We therefore tested for the possibility that lymphocytes were inhibit- 
ing factor B-induced monocyte-mediated eytotoxicity. Table IV shows  that  freshly 
obtained lymphocytes inhibited factor B-dependent monocyte-mediated killing  73- 
100% at a  monocyte/lymphocyte ratio of 2:1. As a  control for nonspecific effects of 
higher cell concentrations in these cultures, a  human  B cell line (RPMI  1056)  was 
also  added  in  a  series  of control experiments,  and  in  no  case was  any  inhibition 
observed. We are currently further characterizing the nature of this inhibitory effect. 
Discussion 
Previously, we showed  (1,  2)  that  human  mononuclear cells can lyse xenogeneic 
erythrocyte target cells in  the presence of heat-labile serum  factors. In  the  present 
report, we  further characterized this  type of cytotoxicity and  presented  data  that 
serum complement components cooperate with mononuclear leukocytes in the lysis of 
target  cells.  We  report  a  series of experiments with  both  whole  mononuclear cell 
effector populations  and  populations  enriched  in  monocytes or  lymphocytes. The 
serum  requirements  for  cooperative  cytotoxicity  have  been  dissected  using  sera 
deficient  in  (or  depleted  of)  single  complement  components  as  well  as  purified 
complement components. By this strategy, we found that, although lymphocytes and 
monocytes are both capable of cooperating with serum  factors in mediating target 
lysis, the serum factor requirements are different for each type of effector cell. 
Monocytes  appear  to  require  only  added  factor  B  to  lyse  chicken  erythrocyte 
targets. This conclusion is based on several pieces of data.  First, we had  previously 
shown that antibodies to factor B markedly inhibit this form of cytotoxicity. Second, 
of all the deficient and depleted sera tested, only factor B-depleted serum failed to 
cooperate with monocytes in target lysis. Purified factor B can reconstitute the activity 
in factor B-depleted serum. Finally, purified factor B in conjunction with monocytes 
leads to target lysis in the absence of other added serum factors. These findings are 
consistent  with  previous  findings  reported  by G/Stze  et  al.  (12,  13)  that  factor  B 
induces macrophage spreading, a morphologic correlate of macrophage activation. 
Lymphocytes appear to require a different set of serum factors to become cytotoxic 
in this system. Experiments with deficient and depleted sera suggest that factor B, C5, 
C7,  and  C8  are all  required.  C3, C4,  and  factor D  appear not  to be  required  for 
lymphocyte-mediated target iysis.  Factor B alone cannot support lymphocyte-medi- 
ated target cell lysis. 
Serum deficient in C3 cooperated normally with whole mononuclear cell popula- 
tions as well as populations enriched in monocytes or lymphocytes, in  target  lysis. 
This finding was surprising in light of the central importance of C3 in the complement HALL, BLAESE, DAVIS,  DECKER,  TACK, COLTEN,  AND MUCHMORE  841 
cascade.  Experiments with monoclonal anti-C3,  designed  to test  for the possibility 
that trace amounts of C3 were sufficient to support killing, were also consistent with 
the hypothesis that  C3  was  not  required in  this system. Furthermore, as discussed 
above, purified factor B alone was sufficient to support killing by monocytes. 
The mechanism by which different complement components cooperate with both 
monocytes and lymphocytes in target cell lysis is not known. It is likely, however, that 
different mechanisms exist for lymphocytes and monocytes. Neither cell type appears 
to  require  C3,  suggesting  a  novel  mechanism  for  generation  of a  new  form  of 
complement activity. Because monocytes require only factor B in the generation of 
cell-mediated cytotoxieity, two of many possible mechanisms include (a)  binding of 
factor B to monocyte surface, followed by direct activation of the monocyte to become 
cytotoxic and (b) proteolytic cleavage by factor B or a fragment of factor B of another 
protein, perhaps associated with effector cell  (monocyte) or target cell surface  The 
mechanism of interaction of lymphocytes with serum complement leading to target 
lysis  similarly  is  open  to  speculation.  In  addition  to  factor  B,  certain  terminal 
components are also required, including C5, C7, C8, and possibly others. Of note in 
this  regard  are  studies  by  Sundsmo  et  al.  (18,  19),  demonstrating  the  presence of 
"neoantigenic" determinants  specific for the  C5b-9  membrane  attack  complex on 
peripheral blood leukocytes. This has been postulated to be involved in the expression 
of cytotoxicity by mononuclear leukocytes. It may be that the system of lymphocyte- 
mediated cytotoxicity described in the present report involves a similar mechanism of 
assembly of complement components on the surface of the effector cell. One possible 
inconsistency, however, is that "neoantigen" was found primarily on non-T cells (18), 
whereas in our system, lymphocyte-mediated cytotoxicity was found primarily in the 
T  cell (E-rosette positive) population (2). 
We have also shown in the present report that, in addition to acting as effector cells 
in  mediating  target  cell  lysis,  lymphocytes  also  may  modulate  the  expression  of 
monocyte-mediated cytotoxicity in  vitro. Thus, lymphocytes markedly inhibit  (73- 
100%) target lysis in the presence of monocytes and factor B. The identification of the 
inhibitory cell as well as the mechanism of inhibition are presently under investigation. 
Two likely possibilities for the mechanism  of inhibition  include  (a)  inactivation of 
factor  B  by  lymphocytes and  (b)  direct  suppression  of cytotoxic monocytes.  The 
observation that monocytes in the presence of lymphocytes (i.e., unseparated mono- 
nuclear cells)  fail to kill the target erythrocytes in factor B-containing C5-deficient 
serum but do kill the targets in sera deficient in C3, C4, C7,.and C8 suggests that C5 
may play a  role in  modulating  the  effects of lymphocytes on  monocyte-mediated 
cytotoxicity. 
In conclusion, the present report further characterizes a novel form of cytotoxicity 
that links two host-defense systems, the serum complement system and mononuclear 
cells.  Among the several unique features of this system is that C3 appears not to be 
required. Both lymphocytes and  monocytes can act as effector cells in this form of 
cytotoxicity, however, probably through different mechanisms. In addition, lympho- 
cytes can also act in vitro to modulate monocyte-mediated cytotoxicity. Such a system 
of cytotoxicity would offer an attractive capability for first line host defense against 
foreign cells in vivo. 
Summary 
Synergistic cytotoxicity is  a  term  used  to  describe  a  cytotoxic system  in  which 
xenogeneic erythrocyte target cells are lysed in the presence of nonimmune human 842  COMPLEMENT-MONONUCLEAR  CELL COOPERATIVE CYTOTOXICITY 
mononuclear effector cells and antibody-depleted normal human serum. Neither the 
mononuclear cells nor the serum alone are cytolytic to the target erythrocytes. Previous 
studies have shown that the serum activity is not immunoglobulin and is heat-labile, 
suggesting a similarity to serum complement.  In this report, sera deficient in various 
complement  components  as well  as  highly purified  single complement  components 
were  tested  with  whole  mononuclear  cell  populations  and  purified  monocytes and 
lymphocytes to further characterize this cytotoxicity system. Whole mononuclear cell 
populations  failed  to  mediate  target  cell  lysis  in  sera  deficient  in  C5  or  factor  B. 
However,  C3-deficient  serum,  even  in  the  presence of anti-C3  antibody,  supported 
synergistic cytotoxicity normally.  Purified lymphocytes were also normally cytotoxic 
in  C3-deficient  serum  but  failed  to lyse targets  in  sera  deficient  in  C5,  C7,  C8,  or 
depleted of factor B. Purified monocytes failed to lyse the target cells only in factor B- 
depleted serum and could lyse the target  cells in serum-free medium when purified 
factor B alone was added.  Monocyte-mediated cytotoxicity induced by factor B was 
inhibited  73-100%  by adding  lymphocytes back  to  the  purified  monocytes.  Thus, 
both lymphocytes and monocytes can serve as effector cells in this form of cytotoxicity 
but require cooperative interaction with different sets of complement components, In 
addition, lymphocytes can modulate the monocyte-mediated form of target cell lysis 
associated with factor B. 
Received  for publication 14 April  1982. 
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